Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 12/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29722781 | 1.00 | GHSR (0.49) | GHSRHDAC8ALOX15TSHRHSD17B10 | |
| SCHEMBL24529063 | 0.89 | GHSR (0.45) | GHSRHDAC8 | |
| SCHEMBL30645332 | 0.89 | GHSR (0.45) | GHSRHDAC8 | |
| SCHEMBL3069044 | 0.87 | GHSR (0.63) | GHSR | |
| SCHEMBL30645350 | 0.87 | GHSR (0.47) | GHSR | |
| SCHEMBL27191463 | 0.87 | GHSR (0.47) | GHSR | |
| SCHEMBL29722749 | 0.85 | GHSR (0.51) | GHSRHDAC8ALOX15TSHRHSD17B10 | |
| SCHEMBL24528897 | 0.85 | GHSR (0.51) | GHSRHDAC8ALOX15TSHRHSD17B10 | |
| SCHEMBL24528881 | 0.83 | ESR2 (0.51) | GHSR | |
| SCHEMBL30645344 | 0.83 | ESR2 (0.51) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | PSMG3, MYCBP2, PSME2 | GHSR 4309/4885HDAC8 2771/4885ALOX15 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.